Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Make a selection below to explore our full database of 6 results matching: "C Recknor"
ACE Reports
(6 Reports)
ACE Reports
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Peri-Operative
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
J Bone Miner Res. 2023 01-Oct;():. 10.1002/jbmr.4877
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
J Bone Miner Res. 2023 01-Oct;():. 10.1002/jbmr.4877
General Orthopaedics
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
J Bone Miner Res. 2022 01-Dec;():. 10.1002/jbmr.4719
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
J Bone Miner Res. 2022 01-Dec;():. 10.1002/jbmr.4719
Metabolic Disorders
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
Metabolic Disorders
Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT
Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21
Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT
Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21
General Orthopaedics
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial
Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial
This report has been verified by one or more authors of the original publication.
Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20
General Orthopaedics
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17